These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7476326)

  • 1. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
    Tazuma S; Takizawa I; Kunita T; Mizuno T; Watanabe T; Teramen K; Horikawa K; Ochi H; Yamashita Y; Aihara N
    Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fluvastatin on human biliary lipids.
    Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
    Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
    Tazuma S; Yamashita G; Ochi H; Miura H; Kajihara T; Hattori Y; Miyake H; Nishioka T; Hyogo H; Sunami Y; Yasumiba S; Kajiyama G
    Clin Ther; 1998; 20(3):477-85. PubMed ID: 9663363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
    Hoogerbrugge-vd Linden N; de Rooy FW; Jansen H; van Blankenstein M
    Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of withdrawal of pravastatin on biliary lipid composition in humans.
    Muraca M; Baggio G; Vilei MT; Martini S; Cianci V; Crepaldi G
    Atherosclerosis; 1996 Jun; 123(1-2):133-7. PubMed ID: 8782844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in biliary lipid output after interruption of pravastatin treatment in humans.
    Hillebrant CG; Eriksson M; Nyberg B; Einarsson K
    Eur J Clin Invest; 1996 Dec; 26(12):1160-5. PubMed ID: 9013093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
    Smit JW; van Erpecum KJ; Renooij W; Stolk MF; Edgar P; Doornewaard H; Vanberge-Henegouwen GP
    Hepatology; 1995 Jun; 21(6):1523-9. PubMed ID: 7768495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?
    Smit JW; Van Erpecum KJ; Gadella MM; Van de Heyning BJ; Van Berge-Henegouwen GP
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):197-200. PubMed ID: 8724016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
    Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
    J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol.
    Sharma BC; Agarwal DK; Baijal SS; Saraswat VA
    J Clin Gastroenterol; 1997 Sep; 25(2):433-6. PubMed ID: 9412944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
    Duane WC; Hunninghake DB; Freeman ML; Pooler PA; Schlasner LA; Gebhard RL
    Hepatology; 1988; 8(5):1147-50. PubMed ID: 3047037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia.
    Horiuchi I; Ohya T; Tazuma S; Mizuno T; Takizawa I; Kajiyama G
    Metabolism; 1991 Mar; 40(3):226-30. PubMed ID: 1900342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic transport of cholesterol in normocholesterolemic rats treated with pravastatin, an inhibitor of HMG-CoA reductase.
    Sakono M; Ibi T; Nagao K; Ikeda I; Yamamoto K; Imaizumi K
    Atherosclerosis; 1996 Jul; 124(1):95-102. PubMed ID: 8800497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
    Kallien G; Lange K; Stange EF; Scheibner J
    Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
    Koide K; Hayashi K; Horiuchi I; Kajiyama G
    Biochim Biophys Acta; 1989 Sep; 1005(1):65-71. PubMed ID: 2505850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.
    Tazuma S; Hatsushika S; Aihara N; Sagawa H; Yamashita G; Sasaki M; Sasaki H; Mizuno S; Tao S; Kajiyama G
    Digestion; 1992; 51(3):179-84. PubMed ID: 1521718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
    Hillebrant CG; Nyberg B; Gustafsson U; Sahlin S; Björkhem I; Rudling M; Einarsson C
    Eur J Clin Invest; 2002 Jul; 32(7):528-34. PubMed ID: 12153554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the type of dietary fat on biliary lipid composition and bile lithogenicity in humans with cholesterol gallstone disease.
    Yago MD; González V; Serrano P; Calpena R; Martínez MA; Martínez-Victoria E; Mañas M
    Nutrition; 2005 Mar; 21(3):339-47. PubMed ID: 15797676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver.
    Carrella M; Fong LG; Loguercio C; Del Piano C
    Metabolism; 1999 May; 48(5):618-26. PubMed ID: 10337863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation.
    Muraca M; Baggio G; Miconi L; Vilei MT; Martini S; Gabelli C; Belluco C; Lise M; Crepaldi G
    Eur J Clin Invest; 1991 Apr; 21(2):204-8. PubMed ID: 1905632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.